Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | MAOB | P27338 | 4/20 | 0.56 |
| ▸ | CA12 | O43570 | 2/20 | 0.56 |
| ▸ | CA9 | Q16790 | 2/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA3 | P07451 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | CA4 | P22748 | 1/20 | 0.56 |
| ▸ | CA6 | P23280 | 1/20 | 0.56 |
| ▸ | CA5A | P35218 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30267413 | 0.84 | MIF (0.60) | KDM4EALDH1A1HPGDNPSR1RAB9A | |
| SCHEMBL591197 | 0.84 | MIF (0.60) | KDM4EALDH1A1HPGDNPSR1RAB9A | |
| SCHEMBL14015883 | 0.83 | FLT3 (0.53) | KDM4EALDH1A1HPGDRAB9AMEN1 | |
| SCHEMBL13823093 | 0.81 | CA12 (0.53) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL591072 | 0.81 | MAOB (0.63) | KDM4EALDH1A1HPGDCYP2C19RAB9A | |
| SCHEMBL17903977 | 0.80 | MAOB (0.47) | KDM4EALDH1A1HPGDNPSR1CYP2C9 | |
| SCHEMBL28812863 | 0.79 | KDM4E (0.77) | KDM4EALDH1A1HPGDNPSR1CYP1A2 | |
| SCHEMBL18396230 | 0.78 | MAOB (0.56) | KDM4EALDH1A1HPGDCYP1A2CYP2C19 | |
| SCHEMBL592979 | 0.78 | MAOB (0.69) | KDM4EALDH1A1HPGDNPSR1CYP1A2 | |
| SCHEMBL30790593 | 0.78 | MAOB (0.69) | KDM4EALDH1A1HPGDNPSR1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743593-A1 | MATERIALS AND METHODS FOR DETERMINING GAIN OR LOSS OF MRNA TRANSCRIPTS | Ventana Medical Systems, Inc. (US) | 2026-05-20 | — | — | EP | claimed |
| EP-4709421-A2 | B. BURGDORFERI PEPTIDOGLYCAN ANTIBODIES AND USES THEREOF | Virginia Tech Intellectual Properties, Inc. (US) | 2026-03-18 | — | — | EP | claimed |
| EP-4652196-A1 | NEUROPILIN-1-PEPTIDE BASED ANTIBODY, HIGHLITING NEW EPITOPE ASSOCIATED TO GLYCOSAMINOGLYCAN-MODIFIED NEUROPILIN-1 AND METHODS OF USE THEREOF | Theranovir (FR) | 2025-11-26 | — | — | EP | claimed |
| WO-2025059533-A1 | CRISPR ENZYMES AND SYSTEMS | THE BROAD INSTITUTE, INC. (US) | 2025-03-20 | — | — | WO | claimed |
| WO-2025014977-A1 | MATERIALS AND METHODS FOR DETERMINING GAIN OR LOSS OF MRNA TRANSCRIPTS | VENTANA MEDICAL SYSTEMS, INC. (US) | 2025-01-16 | — | — | WO | claimed |
| WO-2025010213-A2 | MEDICAL CUTTING AND DRILL DEVICES HAVING STATIC COMPONENTS, RETRACTABLE SHEATHS, SENSORS, NAVIGATION COMPONENTS, WORKING BLADE BODIES, RAILS, STRUTS, CHANNELS FOR FLUID AND GAS FLOW, HAND-PIECE, ROBOTIC ARM ATTACHMENT CAPABILITIES, COMPUTING DEVICES, AND ASSOCIATED FEEDBACKS AND OUTPUTS | Innovations 4 Surgery, LLC (US) | 2025-01-09 | — | — | WO | claimed |
| WO-2024233792-A2 | B. BURGDORFERI PEPTIDOGLYCAN ANTIBODIES AND USES THEREOF | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2024-11-14 | — | — | WO | claimed |
| WO-2024182756-A2 | CELL-SPECIFIC CIS-REGULATORY ELEMENTS, USES THEREOF, AND METHODS OF GENERATING THE SAME | THE BROAD INSTITUTE, INC. (US) | 2024-09-06 | — | — | WO | claimed |
| WO-2024153818-A1 | NEUROPILIN-1-PEPTIDE BASED ANTIBODY, HIGHLITING NEW EPITOPE ASSOCIATED TO GLYCOSAMINOGLYCAN-MODIFIED NEUROPILIN-1 AND METHODS OF USE THEREOF | Theranovir (FR) | 2024-07-25 | — | — | WO | claimed |
| US-20260144201-A1 | METHOD OF IDENTIFYING TARGET SPOT-RESISTANT GLYCINE PLANTS | TMG TROPICAL MELHORAMENTO E GENÉTICA S.A. (BR) | 2026-05-28 | — | — | US | disclosed |
| EP-4747121-A1 | SPECIALIZED AND SELF-LEARNING NODES | Toyota Motor North America, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4748093-A2 | ROUTE INTELLIGENCE FOR CITY NODES | Toyota Motor North America, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4743593-A1 | MATERIALS AND METHODS FOR DETERMINING GAIN OR LOSS OF MRNA TRANSCRIPTS | Ventana Medical Systems, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-12628850-B2 | Enzymatically stabilized pasta structure and method of preparing the same | MUHLENCHEMIE GMBH & CO. KG (DE) | 2026-05-19 | — | — | US | disclosed |
| EP-3276349-B1 | HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE | VENTANA MED SYST INC (US) | 2019-08-07 | — | — | EP | disclosed |
| EP-3276349-A1 | HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE | Ventana Medical Systems, Inc. (US) | 2018-01-31 | — | — | EP | disclosed |
| EP-3029461-B1 | HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE | VENTANA MED SYST INC (US) | 2017-12-20 | — | — | EP | disclosed |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | EXCRX (SINGAPORE) PTE. LTD. (F.K.A. COMBINATORX (SINGAPORE) PTE LTD.) (SG) | 2008-07-03 | — | — | US | disclosed |
| WO-2008033466-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PRE. LTD. (SG) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | KDM4E 192/4885ALDH1A1 2240/4885HPGD 3754/4885 |
| US-20260144201-A1 | METHOD OF IDENTIFYING TARGET SPOT-RESISTANT GLYCINE PLANTS | METTL16, GDA, GNMT | KDM4E 2108/4885ALDH1A1 3951/4885HPGD 2902/4885 |
| US-12628850-B2 | Enzymatically stabilized pasta structure and method of preparing the same | AGL, UCHL5, UCHL3 | KDM4E 237/4885ALDH1A1 609/4885HPGD 2202/4885 |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, EIF2AK2, RNASE1 | KDM4E 861/4885ALDH1A1 785/4885HPGD 1817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.